CA2318231A1 - Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune - Google Patents

Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune Download PDF

Info

Publication number
CA2318231A1
CA2318231A1 CA002318231A CA2318231A CA2318231A1 CA 2318231 A1 CA2318231 A1 CA 2318231A1 CA 002318231 A CA002318231 A CA 002318231A CA 2318231 A CA2318231 A CA 2318231A CA 2318231 A1 CA2318231 A1 CA 2318231A1
Authority
CA
Canada
Prior art keywords
tumor
igm
antibodies
tissue
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318231A
Other languages
English (en)
Inventor
Paul E. Borchardt
Huibert M. Vriesendorp
Syed M. Quadri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
IQ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IQ Corp filed Critical IQ Corp
Publication of CA2318231A1 publication Critical patent/CA2318231A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

On a trouvé que l'on pouvait utiliser de grands agrégats d'anticorps ou des molécules telles que l'immunoglobuline M, l'immunoglobuline G conjuguée ou les protéines de fusion de l'immunoglobuline G pour traiter des tumeurs par administration intra-compartimentale ou intratumorale d'un anticorps antitumoral couplé à une toxine. Le traitement convient également contre certains troubles caractérisés par le dépôt d'un complexe immun, et notamment la polyarthrite rhumatoïde. Selon la réalisation préférée, l'anticorps est l'immunoglobuline M, et la toxine est un radio-isotope, et de façon plus préférentielle une immunoglobuline M radiomarquée par le ?111¿In ou le ?90¿Y. Les exemples mettent en évidence l'efficacité sur des modèles murins.
CA002318231A 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune Abandoned CA2318231A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US862098A 1998-01-16 1998-01-16
US09/008,620 1998-01-16
PCT/US1999/000857 WO1999036105A2 (fr) 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune

Publications (1)

Publication Number Publication Date
CA2318231A1 true CA2318231A1 (fr) 1999-07-22

Family

ID=21732655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318231A Abandoned CA2318231A1 (fr) 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune

Country Status (5)

Country Link
EP (1) EP1047457A2 (fr)
JP (1) JP2002509122A (fr)
AU (1) AU3544599A (fr)
CA (1) CA2318231A1 (fr)
WO (1) WO1999036105A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030091978A (ko) * 2001-01-29 2003-12-03 아이덱 파마슈티칼즈 코포레이션 변형된 항체 및 사용 방법
WO2002096948A2 (fr) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Anticorps tetravalents modifies et procedes d'utilisation
EP2204190A1 (fr) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha Production d'IgM par des cellules transformées et procédés pour la quantification de ladite production d'IgM
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
AU2008311076B2 (en) * 2007-10-09 2014-06-12 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Laminins, derivatives, and compositions including same and method for their therapeutic use
KR102289054B1 (ko) * 2019-03-29 2021-08-19 한국수력원자력 주식회사 저선량방사선에 의한 류마티스 관절염 예방

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292868A (en) * 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
WO1990015625A1 (fr) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPIE UTILISANT UNE EMISSION DE PARTICULES $g(a)
AU663582B2 (en) * 1992-03-04 1995-10-12 Akzo N.V. In vivo binding pair pretargeting
CN1201005C (zh) * 1996-05-22 2005-05-11 维文蒂阿生物技术股份有限公司 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途

Also Published As

Publication number Publication date
JP2002509122A (ja) 2002-03-26
EP1047457A2 (fr) 2000-11-02
WO1999036105A9 (fr) 1999-10-21
AU3544599A (en) 1999-08-02
WO1999036105A2 (fr) 1999-07-22
WO1999036105A3 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
Press et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Wilder et al. Radioimmunotherapy: recent results and future directions.
DeNardo et al. Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies
Epenetos et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.
JP3936339B2 (ja) 調節された浄化時間を有する修飾抗体
EP0118365B1 (fr) Anticorps monoclonaux contre les cellules carcinomateuses mammaires humaines et leur application en diagnostic et en thérapie
JP5855209B2 (ja) 放射免疫コンジュゲートおよびその使用
AU4424589A (en) Vasopermeability-enhancing conjugates
Buckman et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3
Govindan et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel
Vaickus et al. Biotechnology Update: Overview of Monoclonal Antibodies in the Diagnosis and Therapy of Cancer
Herpst et al. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
EP0288520B1 (fr) Usage et composition permettant d'ameliorer le ciblage d'anticorps, de fragments d'anticorps, et de leur conjuges
WO1999036105A9 (fr) Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune
Kosmas et al. Monoclonal antibody targeting of ovarian carcinoma
Abrams et al. Monoclonal antibody therapy of solid tumors
Gerretsen et al. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG
Quadri et al. Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12
Oldham et al. Individually specified drug immunoconjugates in cancer treatment
DeNardo et al. Strategies for enhancement of radioimmunotherapy
Borchardt et al. Indium-111-and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice
Haisma et al. Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man
Leigh et al. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy
de Jonge et al. Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31
Syrigos et al. Radioimmunotherapy of ovarian cancer

Legal Events

Date Code Title Description
FZDE Dead